Achieve Life Sciences, Inc.
NCM: ACHVLive Quote
📈 ZcoreAI Score
Our AI model analyzes Achieve Life Sciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ACHV Z-Score →About Achieve Life Sciences, Inc.
Healthcare
Biotechnology
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
📊 Fundamental Analysis
Achieve Life Sciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -257.7%, which indicates that capital utilization is currently under pressure.
At a current price of $3.49, ACHV currently sits at the 38th percentile of its 52-week range (Range: $1.95 - $6.03).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$185.81M
Trailing P/E
--
Forward P/E
-3.36
Beta (5Y)
1.96
52W High
$6.03
52W Low
$1.95
Avg Volume
653K
Day High
Day Low